OpenAI researcher Miles Wang in talks to launch AI drug discovery startup valued at $2B
Miles Wang, an OpenAI researcher, is leaving the company to start a new AI-driven drug discovery startup. He is reportedly in talks to raise roughly $200 million at a $2 billion valuation, with Lightspeed potentially leading the round. The venture aims to develop models that can repurpose existing drugs and revive candidates that failed in earlier trials.
- ▪Wang’s departure from OpenAI follows his work on AI methods to accelerate scientific discovery.
- ▪Funding discussions suggest investor interest, though Wang has disputed the reported valuation and amount.
- ▪Lightspeed is in talks to lead a potential $200 million financing round for the startup.
- ▪The new company may focus on AI models that identify new uses for FDA‑approved drugs and previously failed compounds.
Opening excerpt (first ~120 words) tap to expand
Miles Wang, an OpenAI researcher whose work includes using AI to accelerate scientific and biological discovery, is leaving the ChatGPT maker to launch a new startup focused on developing AI models for drug discovery, according to four people with knowledge of his plans. Several other OpenAI researchers are expected to join the new company. Wang is in talks to raise about $200 million at a $2 billion valuation, two of the people said. Lightspeed is in discussions to lead the funding round, according to sources. Talks are ongoing, the deal may not be final and details could change. Wang disputed the story’s funding figures and description of the company but did not specify the correct numbers or details. Lightspeed didn’t respond to a request for comment.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at TechCrunch.
Discussion
0 commentsMore from TechCrunch
